• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Icatibant
    / Teva


    Active Ingredient
    Icatibant (as acetate) 30 mg / 3 ml

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled Syringe (solution for injection)

    1 X 3 ml

    partial basket chart 30653

    Dosage

    General accepted dosage is: One subcutaneous injection of Icatibant  (3 ml/30 mg), as soon as signs of attack are detected (e.g. swelling of the skin, especially in the area of the face and neck, or increasing abdominal pain).
    If the condition is not improved in 6 hours, another 3 ml dose may be administered.
    If there is still no improvement, a third dose may be administered after another 6 hours.
    No more than 3 doses in 24 hours and no more than 8 injections of Icatibant in one month!
    See prescribing information for full details.


    Indications

    Treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.


    Contra-Indications

    Hypersensitivity to the active substance or to any of its excipients.


    Special Precautions

    See prescribing information for full details.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel
    CLOSE